Brilaroxazina Uses, Dosage, Side Effects and more
Brilaroxazina (RP5063) is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder. Reviva Pharmaceuticals also intends to investigate RP5063 for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder (ADD/ADHD), and autism. As of May 2015, it is in phase III clinical trials for schizophrenia.
| Trade Name | Brilaroxazina |
| Generic | Brilaroxazine |
| Brilaroxazine Other Names | Brilaroxazina, Brilaroxazine, Brilaroxazinum |
| Type | |
| Formula | C22H25Cl2N3O3 |
| Weight | Average: 450.36 Monoisotopic: 449.1272971 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for the treatment of schizophrenia and schizoaffective disorder.
